Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Ketamine Research Foundation (KRF) is a non-profit organization dedicated to the study and clinical application of Ketamine-Assisted Psychotherapy (KAP). Founded by Dr. Phil Wolfson, the foundation focuses on clinical research, practitioner training, and advocacy for the ethical use of ketamine in treating psychiatric disorders and end-of-life distress. KRF conducts clinical trials, most notably the Indura study, and operates a training institute to certify therapists in specialized KAP protocols. The organization aims to expand access to ketamine treatment while establishing high standards for safety, therapeutic efficacy, and the integration of psychotherapy with pharmacological intervention.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ketamine Research Foundation.